Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Terminated 1Recruiting 1

Sponsor Class

NETWORK 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × GEN-1 × Gynecologic × Clear all
NCT02480374 2024-10-02

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Imunon

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 1 Completed
16 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01118052 2018-01-11

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
22 enrolled 8 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00473954 2013-03-26

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

EGEN, Inc.

Phase 1 Completed
13 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡